-
-
Clinicians are becoming more attuned to the many complications of influenza, particularly with the high morbidity and mortality seen with H5N1 strains spreading around the world.
-
Another monoclonal antibody to TNF-a has been approved for the treatment of Crohn's Disease.
-
In this Issue: Pioglitazone and heart disease; ARBs manufacturers spend
millions to show the non-inferiority of their products compared to less
expensive, generic ACE inhibitors; some athletes turn to growth hormone
because it is difficult to detect; FDA Actions
-
For 2 years beginning in February, 2005, every patient admitted to the Royal Infirmary of Edinburgh with community-acquired pneumonia (CAP) had blood levels of C-reactive protein (CRP) measured at the time of admission and (if still in the hospital) 4 days later. A standardized set of clinical and laboratory data was also acquired for each patient, per hospital routine.
-
Starting 4 months after publication of the ARDS Network's landmark study showing improved outcomes in patients with acute lung injury (ALI) or the acute respiratory distress syndrome (ARDS) when low-tidal-volume, lung-protective ventilation (LPV) was used, investigators at the University of Pennsylvania prospectively identified 88 patients who met the accepted American-European Consensus Conference definition of ALI-ARDS.
-
While only a minority of patients with asthma exacerbations require ICU admission, these patients are challenging to manage because they typically have already failed treatment in the outpatient and emergency department (ED) settings.
-
-
-
A product containing a commonly used antimigraine drug (sumatriptan) and a NSAID (naproxen) has been approved for the treatment of acute migraine attacks.
